Trial Profile

Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary)
Indications Diabetic retinopathy; Eye disorders; Myopia; Retinal disorders; Wet age-related macular degeneration
Focus Therapeutic Use

Most Recent Events

27 Aug 2018 Planned End Date changed from 1 Sep 2017 to 1 Dec 2019.
27 Aug 2018 Planned primary completion date changed from 1 May 2017 to 1 May 2019.
01 Oct 2017 Results (n=60) assessing long-term safety and efficacy of ziv-aflibercept in retinal diseases, were published in the British Journal of Ophthalmology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com